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Thoracic Epidural Anesthesia Can Be Effective for the Short-Term
Management of Ventricular Tachycardia Storm
Duc H. Do, MD; Jason Bradfield, MD; Olujimi A. Ajijola, MD, PhD; Marmar Vaseghi, MD, PhD; John Le, MD; Siamak Rahman, MD;
Aman Mahajan, MD, PhD; Akihiko Nogami, MD, PhD; Noel G. Boyle, MD, PhD; Kalyanam Shivkumar, MD, PhD
Background-—Novel therapies aimed at modulating the autonomic nervous system, including thoracic epidural anesthesia (TEA),
have been shown in small case series to be beneficial in treating medically refractory ventricular tachycardia (VT) storm. However,
it is not clear when these options should be considered. We reviewed a multicenter experience with TEA in the management of VT
storm to determine its optimal therapeutic use.
Methods and Results-—Data for 11 patients in whom TEA was instituted for VT storm between July 2005 and March 2016 were
reviewed to determine the clinical characteristics, outcomes, and role in management. The clinical presentation was incessant VT
in 7 (64%), with polymorphic VT in 3 (27%) and monomorphic VT in 8 (73%). The underlying conditions were nonischemic
cardiomyopathy in 5 (45%), ischemic cardiomyopathy in 3 (27%), and hypertrophic cardiomyopathy, Brugada syndrome, and cardiac
lipoma in 1 (9%) each. Five (45%) had a complete and 1 (9%) had a partial response to TEA; 4 of the complete responders had
incessant VT. All 4 patients with a documented response to deep sedation demonstrated a complete response to TEA.
Conclusions-—More than half of the patients with VT storm in our series responded to TEA. TEA may be effective and should be
considered as a therapeutic option in patients with VT storm, especially incessant VT, who are refractory to initial management.
Improvement in VT burden with deep sedation may suggest that sympathoexcitation plays a key role in perpetuating VT and predict
a positive response to TEA. ( J Am Heart Assoc. 2017;6:e007080. DOI: 10.1161/JAHA.117.007080.)
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T he autonomic nervous system, particularly the sympa-thetic nervous system, plays an important role in the
pathogenesis of ventricular tachycardia (VT) storm.1–3
Neuraxial modulation shows promise in the management
of VT storm. Successful treatment of VT storm with cardiac
sympathetic blockade has been reported with surgical
cardiac sympathetic denervation (CSD),4–7 percutaneous
stellate ganglion block,8,9 and renal sympathetic denerva-
tion.10–12
Thoracic epidural anesthesia (TEA), the infusion of anes-
thetic agents (eg, bupivacaine or opioids) into the epidural
space, is used to achieve sympathetic block at the T1 to T4
levels. TEA has the benefit of rapid onset of action and can be
titrated to wanted effect. Although TEA is used primarily in the
perioperative setting for pain relief, it has the potential benefit
of decreasing general anesthesia requirements and postoper-
ative arrhythmias, particularly in cardiac surgery.13,14 TEA has
been shown to increase the ventricular fibrillation threshold
during acute myocardial ischemia,15 lengthen ventricular
repolarization and effective refractory periods,16 suppress the
effects of ventricular activation recovery interval shortening
and spatial heterogeneity of repolarization caused by sympa-
thoexcitation of the heart17 in animal models, and decrease
arrhythmia burden in VT storm.18 However, its role in the short-
term management of VT storm, the selection of patients likely
to benefit most, and the optimal timing of intervention are not
known, limiting its adoption in clinical practice.
The purpose of the present study was to review our clinical
experience with TEA in the management of VT storm and
propose a systematic approach for optimal patient selection
and timing of intervention. Predictors of response to TEA were
also evaluated.
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Methods
Patient Population
We reviewed data from 11 patients at the Ronald Reagan
UCLA Medical Center (Los Angeles, CA) and Tsukuba
University Hospital (Tsukuba, Japan), who underwent TEA for
the management of VT storm between July 2005 and March
2016. Four of these patients (patients 1–4; Table 1) were
included in a prior case series.18 Review of patient data was
approved by the institutional review board at each institution,
with a waiver for patient consent.
Data Collection
Baseline characteristics, VT/ventricular fibrillation burden,
medical and procedural management of VT/ventricular fibril-
lation, and outcomes up to the time of discharge were
evaluated.
Given that the effects of TEA have a rapid onset, we
evaluated short-term outcomes of TEA by comparing the
number of VT episodes and shocks, whether from an
implantable cardioverter defibrillator or an external defibrilla-
tor, in the 48 hours before TEA placement with that of the
48 hours after epidural anesthesia. A complete response was
defined as complete suppression of VT episodes beginning
20 minutes after epidural anesthetic administration. Partial
response was defined as an 80% to 99% reduction in VT
episodes during this time period.18 Where available, we
evaluated blood pressure measurements immediately before
TEA initiation and 20 minutes after anesthetic administration.
For patients awaiting definitive therapy (catheter ablation,
CSD, or orthotopic heart transplant), we also evaluated
whether interim extubation or weaning of antiarrhythmic
medications was possible.
VT storm was defined as 3 or more sustained episodes of
VT requiring intervention within a 24-hour period, and
incessant VT was defined as continuous sustained VT that
recurred promptly despite repeated intervention for termina-
tion over several hours.19
Procedure
The patient was placed in a right or left lateral decubitus
position. Using a sterile technique, a 17-gauge Touhy or
an 18-gauge Perican needle was inserted via a parame-
dian approach into the T1 to T2 or T2 to T3 interspace
via a standard loss-of-resistance approach (Figure 1).
Next, a 19-gauge Flex-Tip Plus or an 18-gauge Perifix
Softtip epidural catheter was advanced to 5 cm beyond
the needle tip into the epidural space and secured in
place. Lack of blood or cerebrospinal fluid aspiration was
used to exclude intravascular or intrathecal catheter
placement. In nonintubated and sedated patients, the
presence of paresthesia was confirmed after injection of
lidocaine. At initiation of TEA, a 1-mL injection of
bupivacaine, 0.25%, or a 10-mL injection of ropivacaine,
0.20%, was administered via the epidural catheter,
followed by an infusion at 2 mL/h of bupivacaine,
0.25%, or 3 mL/h of ropivacaine, 0.20%. The dose was
titrated according to arrhythmic response.
Statistical Analysis
The Shapiro–Wilks test was used to test for normality.
Normally distributed variables were reported as meanSD,
and nonnormally distributed variables were reported as
median and interquartile range (IQR). Intragroup comparisons
were performed using the Wilcoxon signed-rank test. Statis-
tical significance was determined if P<0.05, with all tests
being 2 tailed. Statistical analysis was performed using JMP
Pro 13.
Results
Patient characteristics and reason for initiation of TEA therapy
are shown in Table 1. Of the 11 patients, 10 were male. The
median age was 62 (IQR, 47–72; range, 34–75) years. Of the
11 patients, 5 (45%) had nonischemic cardiomyopathy with
mean left ventricular ejection fraction of 226%; 3 (27%) had
ischemic cardiomyopathy with mean left ventricular ejection
fraction of 283%; and 1 (9%) each had hypertrophic
cardiomyopathy, Brugada syndrome (previously undiagnosed),
and cardiac lipoma, all with a normal left ventricular ejection
fraction.
Clinical Perspective
What Is New?
• In patients who were seen with ventricular tachycardia
storm, refractory to medical management and initiation
catheter ablation, for which thoracic epidural anesthesia
was administered, more than half had complete or >80%
reduction in ventricular tachycardia episodes; a documented
response in ventricular tachycardia burden to deep sedation
appears to predict a positive response to thoracic epidural
anesthesia.
What Are the Clinical Implications?
• Thoracic epidural anesthesia should be considered in
patients with ventricular tachycardia refractory to initial
medical and/or ablation therapy and who do not have
absolute contraindications to epidural catheter placement
while awaiting definitive therapy.
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Clinical Presentation and Initiation of TEA
Initiation of TEA was performed at a median of 7 (IQR, 2–11;
range, 1–26) days from admission or transfer, done at the
discretion of the treating electrophysiologist. The clinical
presentation was incessant VT in 7 patients (64%). VT
morphologic features were polymorphic in 3 (27%) and
monomorphic in 8 (73%). The primary indication for TEA
initiation was persistent episodes of sustained VT in 10 (91%)
and incessant runs of nonsustained VT in 1 (9%), despite
administration of 2 or more antiarrhythmic drugs (Table 2)
and correction of any electrolyte abnormalities to maintain
potassium level >4.0 mmol/L and magnesium level
>2.0 mEq/L. Six patients (55%) had undergone catheter
Table 1. Clinical Presentation
Patient
Age, y/
Sex Cardiomyopathy LVEF, %
Time From
Admission
to TEA, d*
Clinical
Scenario
VT
Classification Indication for TEA
1 75/M ICM 30 1 Incessant VT PMVT Persistent VT on AAD, bridge to ablation
2 54/M NICM 20 7 VT storm MVT Persistent VT on AAD, hypotension from AAD, bridge to OHT
3 66/M HCM 60 26 VT storm MVT Persistent VT on AAD, ablation failed, bridge to OHT
4 75/M NICM/sarcoid 20 11 VT storm MVT Persistent VT on AAD, hypotension from AAD, ablation failed
5 34/M Cardiac lipoma 60 7 Incessant VT MVT Persistent VT on AAD, endocardial ablation failed, bridge to
surgery
6 66/F NICM 30 7 VT storm PMVT Persistent VT on AAD, hypotension and bradycardia from AAD
7 47/M NICM 15 23 Incessant VT MVT Persistent VT on AAD, ablation failed
8 37/M Brugada
syndrome
50 2 Incessant VT PMVT Persistent VT on AAD, bradycardia on AAD
9 72/M ICM 30 3 Incessant VT MVT Persistent VT on AAD, ablation failed
10 58/M NICM 23 3 Incessant VT MVT Incessant runs of NSVT on AAD after unsuccessful ablation
11 62/M ICM 30 2 Incessant VT MVT Persistent VT on AAD, endocardial ablation and right stellate
ganglionectomy (referring center) failed, bridge to repeated
ablation
AAD indicates antiarrhythmic drug; HCM, hypertrophic cardiomyopathy; ICM, ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; MVT, monomorphic ventricular tachycardia;
NICM, nonischemic cardiomyopathy; NSVT, nonsustained ventricular tachycardia; OHT, orthotopic heart transplant; PMVT, polymorphic ventricular tachycardia; TEA, thoracic epidural
anesthesia; VT, ventricular tachycardia.
*This does not include days at outside hospitals before transfer.
Figure 1. Anatomy of thoracic epidural catheter placement for the management of ventricular
tachycardia storm.
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ablation for VT during the same hospitalization, with early
recurrence (Figure 2). TEA was initiated in 3 patients with the
intention to bridge to catheter ablation (initial in 2 and repeat
in the third), and orthotopic heart transplant was initiated in
another 2 patients.
Eight patients (73%) were intubated and deeply sedated to
suppress VT at the time of TEA initiation, and 3 patients (27%)
had an intra-aortic balloon pump for hemodynamic support.
Four intubated patients (50%) had documented improvement
in VT burden with deep sedation (Table 2).
Response to TEA
Pre- and post-TEA administration hemodynamics were avail-
able in 5 patients, with median mean arterial pressure of 71
(IQR, 61–83) mm Hg pre-TEA and 71 (IQR, 58–83) mm Hg
post-TEA (P=1.0; Figure 3). Pre- and post-TEA telemetry strips
for measurement of electrocardiographic intervals in non-
paced rhythms were available in 3 patients. In these patients,
there was no significant difference in PR, QRS duration, or
QTc, with median change of 0 (IQR, 10 to 0; P=1.0), 0 (IQR,
0–0; P=1.0), and 0 (IQR, 20 to 5; P=1.0) milliseconds,
respectively. Five patients (45%) had a complete response to
TEA (patients 6, 8, and 11 had no shocks; patient 1 had a
single VT episode requiring external shock 10 minutes after
bupivacaine administration; and patient 5 had 2 VT episodes
between 15 and 20 minutes after ropivacaine administration,
which was treated with antitachycardia pacing; both had no
further episodes). A sixth patient (patient 2) had a partial
response with 1 episode of VT without implantable car-
dioverter defibrillator shock 17 hours after TEA initiation; in
this patient, the bupivacaine infusion rate was increased to
3 mL/h, with no further episodes recorded (Table 3 and
Figure 4). Inotropes (low-dose dopamine, infused at a rate of
<3 µg/kg per minute) were continuously required in 3
patients who responded to TEA (patients 1, 2, and 6) and 1
patient who did not respond to TEA (patient 7). Dopamine was
weaned off in patients 1 and 6 as esmolol infusion was
decreased after TEA initiation.
Of the 5 complete responders, 4 (patients 1, 5, 8, and 11)
had incessant VT. VT episodes and shocks decreased from a
median of 65 and 50, respectively, to 0 in all of these patients
after 20 minutes of therapy with TEA.
All 4 patients who responded to deep sedation had a
complete response to TEA. Both patients 5 and 11 had
incessant VT episodes, with any weaning of sedation before
TEA; after TEA initiation, they were extubated after 48 and
12 hours, respectively.
Patients 1 and 6 were weaned off esmolol and pro-
cainamide, respectively, without recurrence of VT before
undergoing VT ablation and bilateral stellate ganglionectomy,
respectively.
Patient 10 (who initially had incessant VT and under-
went ablation) had worsening of nonsustained VT runs
Table 2. Treatments Before TEA Initiation
Patient AAD Other Failed AAD
Intubated
(Time Before, d)
Improvement With
Deep Sedation
LV Support
Device
VT Ablation During Current Hospitalization
Before TEA*
1 Amiodarone IV, esmolol Mexiletine Yes (1) No† NA
2 Amiodarone IV, lidocaine Sotalol, dofetilide No NA NA
3 Amiodarone IV, lidocaine,
esmolol
Sotalol No NA Endo (26 d before), surgical
myomectomy (15 d before)
4 Amiodarone IV, lidocaine Yes (2) No† Epi-Endo (2 d before)
5 Amiodarone IV, landiolol,
nifekalant
Yes (1) Yes None
6 Procainamide IV, esmolol Amiodarone Yes (0) Yes NA
7 Amiodarone IV, lidocaine Yes (23) No IABP Endo (23 d before), Endo (7 d before)
8 Esmolol, quinidine Yes (2) Yes IABP NA
9 Amiodarone IV, lidocaine,
esmolol
Yes (4) Unable to assess‡ IABP Endo (1 d before)
10 Lidocaine, esmolol No NA Endo (3 d before)
11 Amiodarone IV, procainamide IV,
esmolol
Lidocaine Yes (12) Yes Endo (13 d before, referring center)
AAD indicates antiarrhythmic drug; Endo, endocardial; Epi, epicardial; IABP, intra-aortic balloon pump; IV, intravenous; LV, left ventricle; NA, not applicable; TEA, thoracic epidural
anesthesia; VT, ventricular tachycardia.
*Includes ablations performed at referring centers before transfer if during the same hospitalization.
†Sedation limited by hypotension.
‡Intubation initiated simultaneously with several other therapies.
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after TEA, which were eventually linked to a gastroe-
sophageal junction perforation (the cause remains
unclear, but in retrospect, symptoms were noted 2 days
before TEA initiation). After surgical repair, the nonsus-
tained VT burden improved, and he was transitioned to
oral antiarrhythmics.
Figure 2. Management of ventricular tachycardia storm in study cohort. The flow chart summarizes how patients were managed before and
after initiation of thoracic epidural anesthesia in our study cohort. Management with dual antiarrhythmic therapy failed in all patients, and initial
interventions, both percutaneous and surgical, before initiation of thoracic epidural anesthesia, had failed in most patients. Endo indicates
endocardial; Epi, epicardial; ICD, implantable cardioverter defibrillator; IV, intravenous; VT, ventricular tachycardia.
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Seven patients (64%) survived to discharge, 2 after
orthotopic heart transplant. Two patients (patients 6 and 7)
were bridged to CSD: patient 6 had complete suppression of
VT with TEA but had VT recurrence after CSD (and discon-
tinuation of TEA); patient 7 did not respond to TEA but had
complete VT suppression after CSD and remains well 5 years
later despite declining an implantable cardioverter defibrilla-
tor.
Discontinuation of TEA
TEA was continued for a median of 4 (IQR, 2–9; range, 1–15)
days. In 3 cases, the patient died, with the epidural catheter
remaining in place (Table 3). Concern for catheter infection in
the setting of fevers was the reason for discontinuation in 2
patients, but other sources were found in both; tip culture
results were negative. Concern for infection risk because of
prolonged therapy was cited for 2 patients (at 9 and 15 days
after insertion). Resolution of VT was the reason for discon-
tinuation in the other 6 patients.
Anticoagulation Management
All anticoagulation was withheld in 6 patients (55%), including
all 3 with an intra-aortic balloon pump; prophylactic dose
heparin only was continued in 4 other patients (36%). Only
patient 7 had his intra-aortic balloon pump removed while the
epidural catheter remained in place, done without a prolonged
weaning period. No episodes of arterial emboli were noted in
any patient. Patient 1 received therapeutic anticoagulation
during his endocardial VT ablation.
Complications and Adverse Effects of TEA
No procedural complications associated with insertion or
removal of the epidural catheter were identified. No epidural
hematomas or infections occurred. Hypotension was noted in
patient 7 when the infusion rate of bupivacaine was increased
to 5 mL/h, leading to a reduction in dosage back to 4 mL/h,
with resolution of hypotension.
Discussion
Our study shows that TEA can be performed safely in patients
who are seen with VT storm, and it can be effective in a
subset of patients in whom initial therapies, including
antiarrhythmic medications, sedation, and ablation, are not
effective.
Rationale for Use of TEA in VT Storm
The role of CSD for the management of ventricular arrhyth-
mias in humans has been well established, exerting its effects
by transiently decreasing cardiac tissue norepinephrine,
increasing the threshold for ventricular arrhythmias, and
reducing spatial heterogeneity in repolarization and depolar-
ization.3,20 Bilateral thoracic sympathectomy was first
described by Estes and Izlar4 in 1961 to successfully treat a
35-year-old man with incessant runs of VT, refractory to
medical therapy. Since then, CSD by surgical left or bilateral
stellate ganglionectomy has been used successfully to
manage recurrent ventricular arrhythmias in patients with
long QT syndrome, catecholaminergic polymorphic VT, idio-
pathic VT, and VT associated with structural heart dis-
ease.5,21–25
However, in the short-term setting with an unstable
patient, particularly a patient with incessant VT, surgical
CSD may be neither feasible nor desirable. Rapidly acting and
reversible methods of cardiac sympathetic blockade may be
preferred in these scenarios, particularly to stop the vicious
cycle of repetitive defibrillator shocks, which can cause
psychological distress, potentiate heart failure, and perpetu-
ate the heightened sympathetic state that sustains VT
storm.18 For patients with recurrent VT after antiarrhythmic
drug administration, deep sedation with intubation is the most
commonly used method to reduce sympathoexcitation and
avoid further arrhythmias and shocks while awaiting definitive
treatment.
In comparison to TEA, deep sedation with intubation can
be initiated more rapidly. However, mechanical ventilation and
deep sedation can cause hypotension in patients with already
compromised cardiac function, limiting the depth of sedation
achievable without depending on highly arrhythmogenic
inotropes. Prolonged intubation also carries risks that can
Figure 3. Hemodynamic response to thoracic epidural anesthe-
sia (TEA). Mean arterial blood pressure immediately before and
20 minutes after initial TEA administration in 5 patients. No
significant change in blood pressure was seen before and after
TEA in these patients (Wilcoxon signed-rank test, P=1.0).
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contribute to morbidity/mortality.26–28 TEA directly blocks
sympathetic neurotransmission to the heart and may be more
effective than deep sedation in this regard, with potentially
fewer off-target adverse effects, such as hypotension.29
Hence, TEA may serve as a substitute for deep sedation. In
those patients who are already intubated and are likely to
require deep sedation for a prolonged period (>48 hours)
before definitive therapy, TEA can serve as a bridge to allow
for weaning of sedation and earlier extubation. This has the
potential added benefits of allowing patients to participate in
their own medical decision making and for more careful
planning of definitive therapies. In some patients, TEA is
sufficient to break the vicious cycle of VT storm perpetuated
by sympathetic surge after shocks, allowing for effective
suppression of VT with antiarrhythmics alone, before any
definitive interventions are performed.
Risks and Benefits of TEA
TEA can be initiated at the bedside or under fluoroscopy,
which can help confirm catheter placement in sedated
patients in whom sensory testing is not feasible. In experi-
enced centers, the rate of complications is low: epidural
hematomas occur at a rate of 1:20 00030; infections,
including epidural abscess, occur at a rate of 1:1000; and
meningitis occurs at a rate of 1:5000.31 Such complications,
however, are serious, so careful selection of patients most
likely to benefit from TEA is important.
Patient Selection
VT storm represents a complex interaction of a vulnerable
substrate or predisposing channelopathy and inciting triggers,
including electrolyte imbalances, high sympathetic tone,
triggering premature extrasystoles, and ischemia.32–34 Dis-
cerning which serves as the primary cause or perpetuating
factor is often difficult in patients without an obvious ischemic
cause. In this series, TEA responders included those with
many types of cardiomyopathies and both monomorphic and
polymorphic VT; most had incessant VT, suggesting a
potential common factor of sympathoexcitation as the
perpetuating mechanism. A decrease in VT burden with deep
sedation, even if partial, suggests that sympathoexcitation
plays a key role in perpetuating VT in that patient. This may
explain why all such patients in our study responded
completely to TEA. It is not clear, however, whether patients
Table 4. Considerations for Initiation of TEA
Patient factors for which TEA could be considered
Incessant VT despite 2+ antiarrhythmic agents
Continued VT storm despite initial ablation attempt
Decrease in VT burden to deep sedation
Hypotension limiting deep sedation
Long wait time anticipated before definitive therapy
Absolute contraindications
Active infection
Dual antiplatelet therapy
Requirement for uninterrupted therapeutic anticoagulation
Relative contraindications
Acute myocardial infarction
Active major noncardiac medical or surgical process
TEA indicates thoracic epidural anesthesia; VT, ventricular tachycardia.
Figure 4. Ventricular tachycardia (VT) response to thoracic epidural anesthesia (TEA). Number of sustained VT episodes (A) and shocks (B),
both external and internal, before and after initiation of TEA for each patient. Patient 10 is not included because this patient had only incessant
runs of nonsustained VT.
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who do not have a decrease in VT burden with deep sedation
may still respond to TEA, given the different mechanisms by
which each exerts sympatholytic effects.
Weighing the potential risks and benefits, we believe that
TEA should be considered if the patient: (1) has been ruled out
for other inciting factors, such as acute myocardial infarction
or other major noncardiac medical/surgical problem; (2) is
not currently infected, is receiving dual antiplatelet therapy, or
is requiring uninterrupted therapeutic anticoagulation; and (3)
has incessant VT despite 2 or more antiarrhythmic medica-
tions (Table 4).
Anticoagulation With TEA
Although prophylactic anticoagulation can be resumed a few
hours after epidural catheter insertion or removal, therapeutic
anticoagulation is not recommended while the epidural
catheter is in place. Intra-aortic balloon pump therapy should
be continued at 1:1 support without heparin for the duration
of TEA therapy. In patients requiring uninterrupted anticoag-
ulation, such as those with high intracardiac thrombi burden
or patients receiving extracorporeal membrane oxygenation,
an alternative approach of percutaneous stellate ganglion
block can be considered. However, only several case reports
exist on its use in VT storm outside of the peri–myocardial
infarction period.9,35
TEA Response as Predictor of Response to CSD
Similar to stellate ganglion block,23 the ability for TEA
response to predict CSD response is poor: in combination
with patients included in the study by Bourke et al,18 2
patients had a complete response to TEA but no response to
left CSD, 1 patient had no response to TEA but a complete
response to bilateral CSD, and 2 patients had a compete
response to TEA and had a partial or complete response to
left CSD (1 each). This discrepancy in response between the 2
procedures may reflect the different degrees of autonomic
modulation provided by each: sympathetic blockade with TEA
occurs more centrally from that of the bilateral stellate ganglia
and affects both stellate ganglia; left CSD alone may not be as
effective.5 Sympathetic block with TEA can also be incomplete
because of variability in spread of the anesthetic agent to the
nerve roots or migration of the catheter; objective measure-
ments of its sympatholytic effect are rarely performed.
Limitations
This is a small retrospective study with evolving management
of VT storm. The patients included in this study, particularly
those with incessant VT, also represent some degree of
selection bias given they had to be relatively hemodynamically
stable, not requiring immediate extracorporeal membrane
oxygenation or other ventricular assist device therapy, to
undergo epidural catheter placement. In addition, this study
was conducted at tertiary care centers, where patients with
refractory ventricular arrhythmias are often referred. How-
ever, the insights gained from this study can be applicable to
any center with expertise in TEA.
Conclusions
TEA may be an effective therapy in the short-term manage-
ment of VT storm, especially incessant VT, refractory to initial
therapies. Its minimal adverse effect profile, including
hypotension, makes it a potential alternative to prolonged
intubation and deep sedation in patients refractory to initial
management with antiarrhythmics and/or catheter ablation. A
decrease in VT burden with deep sedation suggests that
sympathoexcitation plays a key role in perpetuating VT and,
thus, may predict patients most likely to respond to TEA.
However, patients requiring dual antiplatelet therapy or
uninterrupted anticoagulation are not candidates for TEA.
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